[Inflammatory bowel disease]

Straatmijer T, Duijvestein M, van Dop W, Stassen L, Derikx M, Bureo, Gonzalez A, Mujagic Z, Pierik M, van Schaik F, Peters C, Derikx L, de Groof J, Bennebroek Evertsz F, van der Bilt J, Visschedijk M, West R, Romkens T, van der Meulen A Ned Tijdschr Geneeskd. 2023 Aug...

Endoscopic and surgical treatment outcomes of colitis-associated advanced colorectal neoplasia: a multicenter cohort study

Derks ME, Te Groen M, Peters CP, Dijkstra G, de Vries AC, Romkens TE, Horjus CS, de Boer NK, Bemelman WA, Nagtegaal ID, Derikx LA, Hoentjen F; Dutch Initiative on Crohn and Colitis. Int J Surg. 2023 Jul 1;109(7):1961-1969. doi: 10.1097/JS9.0000000000000335. Free PMC...

Cost-effectiveness analysis of increased adalimumab dose intervals in Crohn’s disease patients in stable remission: the randomised controlled LADI trial

Jansen FM, van Linschoten RCA, Kievit W, Smits LJT, Pauwels RWM, de Jong DJ, de Vries AC, Boekema PJ, West RL, Bodelier AGL, Gisbertz IAM, Wolfhagen FHJ, Römkens TEH, Lutgens MWMD, van Bodegraven AA, Oldenburg B, Pierik MJ, Russel MGVM, de Boer NK, Mallant-Hent RC,...

Ustekinumab Trough Concentrations Are Associated with Biochemical Outcomes in Patients with Crohn’s Disease

Straatmijer T, Biemans VBC, Moes DJAR, Hoentjen F, Ter Heine R, Maljaars PWJ, Theeuwen R, Pierik M, Duijvestein M, van der Meulen-de Jong AE; Dutch Initiative on Crohn’s and Colitis (ICC). Dig Dis Sci. 2023 Jun;68(6):2647-2657. doi: 10.1007/s10620-023-07822-7. Epub...

Increased versus conventional adalimumab dose interval for patients with Crohn’s disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial

van Linschoten RCA, Jansen FM, Pauwels RWM, Smits LJT, Atsma F, Kievit W, de Jong DJ, de Vries AC, Boekema PJ, West RL, Bodelier AGL, Gisbertz IAM, Wolfhagen FHJ, Römkens TEH, Lutgens MWMD, van Bodegraven AA, Oldenburg B, Pierik MJ, Russel MGVM, de Boer NK,...